PharmaCielo (TSE:PCLO)
:PCLO
PCLO Stock Chart & Stats
C$0.04
<C$0.01(5.56%)
At close: 4:00 PM EST
C$0.04
<C$0.01(5.56%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.17
Previous CloseN/A
Volume2.00K
Average Volume (3M)0.00
Market Cap
C$6.92M
Enterprise ValueC$26.82M
Total Cash (Recent Filing)C$289.24K
Total Debt (Recent Filing)C$18.65M
Price to Earnings (P/E)5.2
Beta-2.58
Next Earnings
May 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding187,983,690
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.55
Price to Sales (P/S)3.24
P/FCF Ratio-8.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Medical/pharma-focused Business ModelPharmaCielo’s focus on the medical and pharmaceutical cannabinoid supply chain targets regulated, higher-value end markets rather than commodity recreational channels. That focus supports longer-term contract opportunities, higher product standards and pricing durability versus spot market volatility.
Positive Gross Margin On Core OperationsA positive gross margin (~29%) indicates the core cultivation and processing operations can produce product at a cost below selling prices. This operational efficiency provides a structural opportunity to reach profitability if overhead and SG&A are controlled and revenue stabilizes.
Improving Cash Burn TrajectoryReported improvement in cash outflows versus earlier years reflects progress on cost control and operational discipline. A sustained reduction in burn improves survival odds, reduces immediate refinancing pressure and creates runway to execute strategic initiatives.
Bears Say
Declining Revenue TrendA 16.6% TTM revenue decline undermines the company’s ability to cover fixed cultivation and processing costs, limiting margin recovery. Persistent top-line contraction erodes scale economics, reduces bargaining power with buyers, and raises the likelihood of prolonged unprofitability.
Negative Equity And High LeverageSignificantly negative equity and elevated debt versus a small asset base materially weaken financial flexibility. This capital-structure stress increases refinancing and solvency risk, constrains investment capacity and could force dilutive or onerous financing terms over the medium term.
Continued Negative Cash Flow And Deep LossesSustained negative operating and free cash flow combined with severe operating and net losses require ongoing external funding to sustain operations. This persistent unprofitability threatens long-term viability absent consistent revenue recovery or significant structural cost reductions.
PharmaCielo News
PCLO FAQ
What was PharmaCielo’s price range in the past 12 months?
PharmaCielo lowest stock price was C$0.04 and its highest was C$0.17 in the past 12 months.
What is PharmaCielo’s market cap?
PharmaCielo’s market cap is C$6.92M.
When is PharmaCielo’s upcoming earnings report date?
PharmaCielo’s upcoming earnings report date is May 04, 2026 which is in 25 days.
How were PharmaCielo’s earnings last quarter?
PharmaCielo released its earnings results on Mar 02, 2026. The company reported C$0.002 earnings per share for the quarter, beating the consensus estimate of N/A by C$0.002.
Is PharmaCielo overvalued?
According to Wall Street analysts PharmaCielo’s price is currently Overvalued.
Does PharmaCielo pay dividends?
PharmaCielo does not currently pay dividends.
What is PharmaCielo’s EPS estimate?
PharmaCielo’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaCielo have?
PharmaCielo has 187,983,690 shares outstanding.
What happened to PharmaCielo’s price movement after its last earnings report?
PharmaCielo reported an EPS of C$0.002 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 20%.
Which hedge fund is a major shareholder of PharmaCielo?
Currently, no hedge funds are holding shares in TSE:PCLO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaCielo
PharmaCielo Ltd., together with its subsidiary, cultivates, processes, produces, and supplies medicinal-grade cannabis extracts, tetrahydrocannabinol, and related products. The company also offers telemedicine software. It serves health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies in Canada and Colombia. The company has a strategic alliance with AssuredTrans Inc. PharmaCielo Ltd. is headquartered in Toronto, Canada.
Technical Analysis
Willow Biosciences Inc
―
MediPharm Labs
―
Nextleaf Solutions
―
Avicanna
―
InnoCan Pharma
―
Options Prices
Currently, No data available
---